New technology from Smith & Nephew offers more efficient uterine fibroid removal

   New technology from Smith & Nephew offers more efficient uterine fibroid

PR Newswire

LONDON, Dec. 18, 2012

LONDON, Dec. 18, 2012 /PRNewswire/ --Smith & Nephew (LSE:SN, NYSE:SNN), the
global medical technology business, today introduced the newest addition to
its innovative TRUCLEAR™ System, the TRUCLEAR ULTRA Reciprocating Morcellator
4.0. Designed specifically for removing uterine fibroids, a health issue that
will impact an estimated 80% of women^i, this new device provides surgeons
with a fast, efficient solution for a hysteroscopic procedure that can help
patients avoid the possibility of a hysterectomy, or surgical removal of the

With a precision-engineered cutting edge and a uniquely designed tip that
allows surgeons to access harder-to-reach fibroids, the TRUCLEAR ULTRA
Reciprocating Morcellator 4.0 offers a resection rate more than twice that of
the leading competitor (laboratory testing on analog tissue^ii). Also, because
TRUCLEAR ULTRA removes fibroids through hysteroscopic morcellation, or
mechanical cutting, it requires no incisions or electrical energy to be used
in the uterus and can be performed as an outpatient procedure.

"With the TRUCLEAR System, I have the confidence to safely and effectively
resect submucosal fibroids and endometrial polyps under constant
visualization," says David A. Stone, M.D., FACOG, who practices in
metropolitan Detroit. "While using the TRUCLEAR ULTRA, I was able to remove a
2.5 centimeter diameter submucosal fibroid in a matter of a few minutes. Using
this system can help preserve a woman's future fertility by minimizing damage
to the uterus."

Uterine fibroids are estimated to cost the U.S. healthcare system over $6
billion every year^iii. The most common surgical recommendation for these
non-cancerous growths is to remove the uterus through a hysterectomy. For
women, a hysterectomy means a hospital stay, four to eight weeks of recovery
time, the added risk of infection, and the potential for long-term physical
and psychological effects.

"Fibroids are one of the most significant diseases that women face," explains
Mira Sahney, General Manager, Gynecology for Smith & Nephew. "Our new device
offers a woman with uterine fibroids a considerably less invasive treatment
option that may help preserve her ability to have children."

Smith & Nephew has a growing presence in the market to provide women with
less-invasive treatment options for uterine care. The company continues to
innovate in this area and provides surgeons with options for performing
polypectomies and myomectomies safely and effectively under continuous, clear

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping
improve people's lives. With leadership positions in Orthopaedic
Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith &
Nephew has almost 11,000 employees and a presence in more than 90 countries.
Annual sales in 2011 were nearly $4.3 billion. Smith & Nephew is a member of
the FTSE100 (LSE: SN, NYSE: SNN).

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and
trading margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target", "consider" and
similar expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual results to
differ materially from what is expressed or implied by the statements. For
Smith & Nephew, these factors include: economic and financial conditions in
the markets we serve, especially those affecting health care providers, payors
and customers; price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals, reimbursement
decisions or other government actions; product defects or recalls; litigation
relating to patent or other claims; legal compliance risks and related
investigative, remedial or enforcement actions; strategic actions, including
acquisitions and dispositions, our success in integrating acquired businesses,
and disruption that may result from changes we make in our business plans or
organisation to adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic, business
or competitive nature. Please refer to the documents that Smith & Nephew has
filed with the U.S. Securities and Exchange Commission under the U.S.
Securities Exchange Act of 1934, as amended, including Smith & Nephew's most
recent annual report on Form 20-F, for a discussion of certain of these

Any forward-looking statement is based on information available to Smith &
Nephew as of the date of the statement. All written or oral forward-looking
statements attributable to Smith & Nephew are qualified by this caution. Smith
& Nephew does not undertake any obligation to update or revise any
forward-looking statement to reflect any change in circumstances or in Smith &
Nephew's expectations.

Trademark of Smith & Nephew. Registered US Patent and Trademark Office.

^i US Dept. of Health and Human Services Office on Woman's Health: Uterine
fibroids fact sheet,

^ii Data on file with Smith & Nephew 2012, Reference 15001615.

^iii James Segars, M.D.,; Dec. 20, 2011, American Journal of Obstetrics
and Gynecology online

SOURCE Smith & Nephew

Contact: Brad Merrick, Media, Smith & Nephew, +1-901-399-1089,; or Phil Cowdy, Investor/Analyst, Smith &
Nephew, 44 (0)20 7401 7646,
Press spacebar to pause and continue. Press esc to stop.